



PREDICTORS OF CERVICAL CANCER 
INPATIENT ADMISSION COSTS BY STAGE
Berg GD, Chattopadhyay SK
Centers for Disease Control and Prevention (CDC), Atlanta, 
GA, USA
OBJECTIVES: The objectives were to obtain inpatient
admission cost distributions of cervical cancer by stage of
the disease and to identify significant predictors of cost.
METHODS: 1559 inpatient admission records for the
period 1994–1997 were obtained from MedStat’s private
insurance databases. Costs were measured by total pay-
ments. Probability densities of cost were calculated non-
parametrically for each stage. Regression analyses of cost
per stage were conducted using both nonparametric and
ordinary least squares (OLS) procedures. RESULTS: The
95% quantile of cost ranged from $12,748 for LSIL
(low-grade squamous intraepithelial lesions) to $44,505
for Stage IV cervical cancer. The OLS results show that
Health Maintenance Organizations (HMO) and Point of
Service (POS) plan types have significantly lower costs
than the comprehensive coverage plan (P  0.05) for all
five stages of cervical cancer. The largest difference was
seen in Stage IV with savings of $10,964 for HMO and
$11,544 for POS both compared to the comprehensive
coverage plan. Nonparametric regression analysis con-
firms this finding of statistically significant lower costs
for HMO and POS for all stages except HMO in Stage 2/3
and POS in Stage IV. CONCLUSIONS: It is not clear if
and to what extent the cost advantages of HMO and
POS relative to the comprehensive coverage plan com-
promise the quality of care. The information from the
study may be useful for predicting future costs of treat-
ment for cervical cancer. This may also help policy-makers
in the economic evaluation of cervical cancer screening
programs by providing benchmark values of treatment
cost savings made possible because of earlier detection of
cervical cancer.
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APPLICATION OF PHARMACOECONOMICS 
AND OUTCOMES RESEARCH ON DECISION-
MAKING PATTERNS BY 
MEDICAL ONCOLOGISTS
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Xavier University, College of Pharmacy, New Orleans, LA, 
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The economic burden of cancer is considerable and of
growing concern. The direct medical cost of cancer care
in the US is estimated to be $100 billion per year, about
10% of all health care expenditures, which currently ex-
ceed $1 trillion annually. OBJECTIVES: The two objec-
tives of this research were to assess the extent of use of
pharmacoeconomics and outcomes research in making
therapeutic decisions by oncologists and to determine the
degree of variation in the pattern of therapeutic decision-
making of oncologists. METHOD: A 35-item survey in-
strument was administered by mail to Louisiana regis-
tered medical oncologists. The instrument was designed
to collect data on the demographics, application of phar-
macoeconomic tools and outcomes research (PEOR) to
practice, and decision-making patterns in response to a
clinical case. RESULTS: The oncologists’ mean length of
practice was 15.7 years. The percentages of respondents
applying PEOR measures in the decision of therapy
were as follows: drug cost (66.7%), cost of therapy fail-
ure (40%), pharmaco-/health economic tools (53.3%),
adverse events due to the drug(s) (86.7%), quality of life
(93.3%), and patients’ satisfaction (86.7%). The percent-
age of respondents who chose cyclophosphamide/doxo-
rubicin for first line, a taxane (docetaxel or paclitaxel)
for second line and vinorelbine for third line of therapy
were 46.7%, 66.7% and 46.2%, respectively. The per-
centages of inappropriate choice of anti-emetics for first,
second and third lines of therapy were 15.4%, 54.5%
and 38.5%, respectively. CONCLUSION: The study sug-
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